Ms. Hemrajani currently serves as a member of ALX Oncology’s board of directors and serves as a director at MaxCyte and BioAge Labs. She previously served as the Chief Executive Officer and Director of Jiya Acquisition Corporation, a special-purpose acquisition company. Additionally, she has held C-suite roles at Aravive, Arcus Biosciences, RAPT Therapeutics, and Sagimet Biosciences. Earlier in her career, she was the Vice President, Head of Licensing and M&A at Onyx Pharmaceuticals (acquired by Amgen), and Vice President of Business Development at Exelixis. She started her career in healthcare investment banking at Credit Suisse First Boston and Lehman Brothers. She also serves on the Michigan Biomedical Venture Fund Investment Advisory Board.

Ms. Hemrajani holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.